Transforming growth factor-βl serum concentration in patients with prostatic cancer and benign prostatic hyperplasia

British Journal of Urology

Volumn 81, Issue 3, 1998, Pages 403-405

  Wolff, J M ^a   Fandel, T ^a   Horchers, H ^a   Brehmer Jr , B ^a   Jakse, G ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Prostatic disease; Transforming growth factor 1; Tumour markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0031816554     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Parker SL, Tong T, Bolden S, Wings PA. Cancer statistics 1996. ÇA Cancer] Clin 1996; 46: 5-29
2. Rosen MA. Impact of prostate-specific antigen screening on the natural history of prostate cancer. Urology 1995: 46: 757-68
3. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urologie malignancy. / Urol 1995; 153: 1085-96
4. Yang EY. Moses HL. Transforming growth factor l induced changes in cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane. / Cd! Biol 1990; 111: 731-41
5. Fontana A, Constam DB, Frei K. Malipiero U. Pfister HW. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Appl Immunol 1992; 99: 1-7
6. Newman MJ. Transforming growth factor beta and the cell surface in tumour progression. Cancer Metastasis Rev 199; 12: 239-54 (CHECK DATE)
7. Ivanovic V, Melman A, Davis-Joseph B. Valcic M. Geliebter ]. Elevated levels of TGF-l in patients invasive prostate cancer. Nature Met! 1995; 1: 282-3
8. Ivanovic V. Melman A, Davis-Joseph B, Geliebter ). Elevated levels of transforming growth factor-l in plasma of patients with advanced stages of prostate carcinoma. / Urol 1995: 153: 296A
9. Derynck R, Goeddel DV, Ullrich A et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707-12
10. Thompson TC, Truong LD, Timme TL et al. Transforming growth factor l as a biomarker for prostate cancer. / Cell Biochem 1992; 16H: 54-61
11. Troung LD, Kadmon D, McCune BK. Flanders KC, Scardino FT, Thompson TC. Association of transforming growth factor- with prostate cancer: an immunohistochemical study.' Hum Pathol 1993: 24: 4-9
12. Kong FM, Anscher MS, Murase T, Abbott BD. Iglehart D, Jirtle RL. Elevated plasma transforming growth factor-l levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155-62
13. Kakehi Y. Oka H, Mitusumori K. Ogawa 0. Yoshida 0. Serum TGF-l levels in patients with prostatic cancer: positive correlation with metastasis and inverse correlation with age. / Urol 1996: 155: 419A
14. Perry KT, Anthony CT, Case T. Steiner MS. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 1997; 49: 151-5
15. Miyazono K, Hellman U, Wernstedt C, Carl-Hendri H. Latent high molecular weight complex of transforming growth factor l: purification from human platelets and structural characterization. / Biol Chem 1988: 263: 6407-15